Success Metrics

Clinical Success Rate
82.1%

Based on 23 completed trials

Completion Rate
82%(23/28)
Active Trials
6(13%)
Results Posted
43%(10 trials)
Terminated
5(11%)

Phase Distribution

Ph phase_2
8
17%
Ph phase_4
2
4%
Ph phase_1
12
26%
Ph phase_3
2
4%
Ph not_applicable
12
26%

Phase Distribution

12

Early Stage

8

Mid Stage

4

Late Stage

Phase Distribution36 total trials
Phase 1Safety & dosage
12(33.3%)
Phase 2Efficacy & side effects
8(22.2%)
Phase 3Large-scale testing
2(5.6%)
Phase 4Post-market surveillance
2(5.6%)
N/ANon-phased studies
12(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.7%

23 of 30 finished

Non-Completion Rate

23.3%

7 ended early

Currently Active

6

trials recruiting

Total Trials

46

all time

Status Distribution
Active(10)
Completed(23)
Terminated(7)
Other(6)

Detailed Status

Completed23
unknown6
Terminated5
Recruiting4
Not yet recruiting3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
46
Active
6
Success Rate
82.1%
Most Advanced
Phase 4

Trials by Phase

Phase 112 (33.3%)
Phase 28 (22.2%)
Phase 32 (5.6%)
Phase 42 (5.6%)
N/A12 (33.3%)

Trials by Status

active_not_recruiting24%
enrolling_by_invitation12%
terminated511%
withdrawn24%
unknown613%
completed2350%
not_yet_recruiting37%
recruiting49%

Recent Activity

Clinical Trials (46)

Showing 20 of 46 trialsScroll for more
NCT00942981

Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography

Completed
NCT03745326Phase 1

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Terminated
NCT07586215

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

Recruiting
NCT06089486Not Applicable

MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation

Recruiting
NCT07263815Not Applicable

EQUIP - Evaluation of Quality of Imaging on a Next-generation Total Body Pet Scan in Comparison to Conventional PET

Active Not Recruiting
NCT06738862

[18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients

Completed
NCT05371054Phase 1

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Completed
NCT06757569Not Applicable

Radialis PET Imager for the Assessment of Neuritic Amyloid Plaque Burden

Recruiting
NCT05211336Phase 1

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Active Not Recruiting
NCT02727972Not Applicable

Examination of Glutamate and mGluR5 in Psychiatric Disorders

Completed
NCT02038608Not Applicable

Compensatory Mechanisms in Parkinson Disease (PD)

Completed
NCT05035407Phase 1

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Terminated
NCT04265209Phase 3

[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

Completed
NCT02356159Phase 1

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Completed
NCT00199615Not Applicable

Follow-up of Patients With Curative-intent Surgical Resection for NSCLC

Completed
NCT06895941

Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer

Withdrawn
NCT03283449Phase 1

Tau PET Imaging in Atypical Dementias

Completed
NCT06691464

FAPI PET/CT to Detect Fibroblast Activity in Non-resolving ARDS

Enrolling By Invitation
NCT04720001

Florbetaben PET Imaging in PPA

Completed
NCT06624267

Test of Reproducibility of [15O]H20-PET Assessment of Brain Perfusion

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
46